Legal and administrative information

Trustees	Diego du Monceau de Bergendal Duncan Jodrell Caroline Artis
Registered office	49 St James's Street London SW1A 1AH
Registered number	272818
Chartered accountant	Melissa Foux nr 8313878 56 Flanders Road London W4 1NG
Bankers	Coutts & Co 440 Strand London WC2R 0QS

Trustee's report 31 December 2025

The Trustees present their report along with the accounts of the Friends of EORTC (the Charity) for the year ended 31 December 2025. The accounts have been prepared in accordance with the accounting policies set out on pages 16 to 18 and comply with the charity's trust deed, the Charities Act 2011 and 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102).

Structure, governance and management
The Charity was established under a Trust Deed in 1976 and is registered with the Charity Commission under charity number 272818.

The Chairman, Comte Diego du Monceau de Bergendal, was appointed a trustee in 2015 on the retirement of the then Chairman, Sir Christopher Mallaby. His fellow trustee, Lady Solti was appointed a trustee in 1998, and Mr Edward Chandler was appointed on 7 October 2020, coinciding with the resignation of Mrs Victoria Agnew who had dedicated 22 years to her role with the organisation. Pr. Duncan Jodrell was appointed on 10 November 2021 to replace Lady Solti. Mrs Caroline Artis was appointed on 7 October 2022. Mr Edward Chandler resigned on March 1, 2023. There is no time limit on the tenure of the trustees. The trustees meet twice a year.

The Board keeps the skill requirements for the Trustee Body under review and if a trustee permanently retires or additional trustees are required, the Board would put in place appropriate procedures to recruit the new trustee(s). The Board would also ensure that appropriate induction and training is provided to all new trustees.

Statement of trustees' responsibilities
The trustees are responsible for preparing the trustees' report and accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the trustees to prepare accounts for each fiscal year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these accounts, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the accounts; and
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the accounts comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Risk management
The Charity does not have any employees, significant contracts or material investments nor is the Charity dependent on grant funding from external sources to maintain its charitable activities. As a result of these limited activities, the Charity is exposed to few significant risks. The principal risk faced by the Charity would be the failure to generate sufficient donations to cover the costs of organising a fundraising event. This is mitigated by the Charity, wherever possible, by raising funds in advance of costs being incurred; carefully planning its

fundraising events; targeting known supporters of the Charity and closely monitoring fundraising costs and donations.

Objectives and Activities

EORTC was set up in 1962 by leading cancer specialists in the EU and Switzerland in order that research on treatment of cancer could be co-ordinated and carried out on a European scale, thereby avoiding duplication and achieving economies of time and money.

The primary object of the Charity, as stated in its governing document, is to support the charitable objects and purposes of EORTC Cancer Research Fund AISBL (ECRF), a charity registered in Belgium. The ECRF was established in 1976, as The EORTC Foundation. This charitable trust was established to support the activities of the EORTC.

The ECRF supports the activities of the EORTC through annual grant payments to the EORTC which are used by the EORTC to fund research into cancer treatments. The Friends of EORTC supports the ECRF by organising fundraising events in the UK and by a major fundraising initiative. The funds raised by the Friends of EORTC are then used to support the activities of the ECRF. The Friends of EORTC makes donations to EORTC on an ad- hoc basis, as determined by the Trustees.

Achievements and Performance

Financial review

The income of the charity declined over that of the previous year, however a major fundraising initiative continued, and private donations were received in 2025. The charity received donations from its supporters amounting to £154,836 (2024 - £40,122).

Total expenditure: £ 152,628 (2024 - £ 42,057).

The charity remains financially stable with a small surplus.

Interest and foreign exchange

The Charity earned £245 in interest in 2025 (2024 – £557) and booked no foreign exchange gains (2024 – none).

The Boots Group, TBG (formerly known as Walgreens Boots Alliance, WBA)

EORTC Cancer Research Fund (formerly the EORTC Charitable Trust) has been in partnership with The Boots Group (formerly WBA, then Alliance Boots) since late 2011. The partnership focused on creating the first pan-European biobank in advanced colorectal cancer, now fully operational in Dresden. Formerly known WBA committed to raising €5 million over five years to support this key research infrastructure. Scientific planning for the project, named SPECTAcolor, began in 2012 with the development of biobanking facilities and identification of participating hospitals.

The success of SPECTAcolor led EORTC to expand to other cancer types, culminating in 2018 with the launch of SPECTA, a unified platform for all cancers, including rare ones, with a central biobank in Luxembourg. That same year, the Group renewed its support through a new €5 million, five-year agreement, reaffirming SPECTA's position as a leading translational research infrastructure

In October 2022, the Group and EORTC launched a new three-year fundraising effort to raise €1.8 million for the OligoRARE study and the E^2-RADIatE platform, which aims to define optimal radiation therapy practices for future clinical standards.

E^2-RADIatE is the only pan-European platform dedicated to radiation oncology research, integrating clinical data with diagnostic imaging, treatment data, economic outcomes, and patient-reported experiences to enhance patient-centred care.

The platform includes several observational cohort studies and clinical trials:

- **OligoCare** (EORTC 1822-RP): the first activated cohort, focuses on patients with oligometastatic disease (cancer spread to a limited number of organs), aiming to identify factors influencing survival after radical radiotherapy. Cancer types studied include breast, lung, prostate, and colorectal.
- **ReCare** (EORTC 2011-RP): collects real-world data on high-dose re-irradiation in cases of recurrence or secondary cancers. It aims to provide evidence on efficacy and safety of re-treatment in the modern radiotherapy era.
- **OligoRARE** (EORTC 1945): a randomized clinical trial evaluating whether SABR (Stereotactic Ablative Body Radiotherapy) improves survival compared to standard care in patients with oligometastatic rare cancers.
- **SPRINT** (EORTC 2387): is the first pan-European Trial within Cohorts (TwiCs), leveraging real-world data from the OligoCare cohort to evaluate treatment strategies for patients with oligometastatic breast, prostate, lung, and colorectal cancers. The study aims to determine whether a single fraction of stereotactic body radiotherapy (SBRT) can be as effective as multi-fraction SBRT, potentially reducing treatment burden while improving patient experience and quality of life.

E^2-RADIatE supports radiotherapy's role as a cornerstone of cancer care, used by half of all patients during treatment. By leveraging advanced technology and structured data collection, the platform contributes to reducing inequities in care and improving outcomes across Europe.

Alliance Healthcare (to be renamed Cencora)
In June 2021, Walgreens Boots Alliance sold its Alliance Healthcare businesses to AmerisourceBergen, now renamed Cencora. Alliance Healthcare, now a wholly owned subsidiary of Cencora, supported the SPECTA platform under its new ownership with half of the initial pledge be raised by the end of the agreement in 2023. In 2024, Cencora contributed an additional $100K towards the platform. The funds raised through the partnership are estimated to cover the current activities of the platform until 2027.

In 2025, with the departure of Mrs Barra from the Cencora Board, ECRF received a donation of $5,000 in honour of her services to their Board. The funds were allocated to E^2-RADIatE relating activities.

Alliance Healthcare (soon to be renamed Cencora) contributions
From June 1st, 2021, to December 2024, 2023, Alliance Healthcare has raised a total of €2,192,401.24. Honouring the original agreement between the former WBA and EORTC.

AMRC - Association of Medical Research Charities
Since October 2014, the Friends of EORTC has been a member of AMRC. This membership provides clear benefits for EORTC and for the costs related to its international clinical studies being opened or adopted in the UK. Membership of AMRC (audited on an annual basis) helps the EORTC to qualify as eligible under the UK NHS AcoRD Programme under which certain clinical research costs are met by the National Health Service.

Under AcoRD, AMRC charities that fund in open competition do not have to pay these costs. The work will be done by the NIHR Clinical Research Networks or will be covered by the infrastructure support funding going to NHS trusts and universities. EORTC, through the Friends of EORTC, is in good standing for support from the NIHR and NHS for other study related costs as described above.

UK Liaison Office
A Liaison Office has been established in the UK between the National Cancer Research Institute (NCRI), EORTC and CR-UK to promote better communications between these three organisations and to facilitate the adoption of EORTC's international studies in the UK and the extension of UK studies into Europe. The Friends of EORTC supports this initiative by currently contributing one third of the costs of the salary of the Liaison Officer, based at the University of Leeds. Since 2017, the costs of the Liaison Office in Leeds have been shared between EORTC and CR-UK.

Investment powers, policy, and performance

The Charity does not hold investments other than cash held on an interest bearing deposit on a short-term basis. These funds are held in the Charity's bank account, held by Coutts.

Grant making policy

The Charity makes grants to the EORTC and to the EORTC Cancer Research Fund and for fellowships, as direct grants or on an ad-hoc basis.

Reserves

The Charity makes grants to the EORTC as cash becomes available, retaining sufficient funds to cover the potential outgoings associated with future fundraising events. The Charity does not enter on-going commitments and therefore does not need to ensure a steady flow of income. For this reason, the trustees do not consider it appropriate to maintain a target level of reserves.

The funds raised by the Charity are held as deposits on call accounts until such time that the Trustees wish to make grants or donations directly to the EORTC to support their ongoing activities.

Going concern

The Trustees of the charity have determined that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The trustees are of the opinion, based on available information at the date of approval of the financial statements, that the charity will have sufficient resources to meet its liabilities as they fall due. They do not believe that there are concerns regarding the charity's ability to continue as a going concern.

Approved by order of the Trustees

Chairman Diego du Monceau

Date 01/10/2026

Independent examiner's report to the trustees of the Friends of EORTC

I report to the trustees on my examination of the accounts of the Friends of EORTC for the year ended 31 December 2025.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by section 130 of the Act; or

2. the accounts do not accord with those records; or

3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: 

Name: Melissa Foux

Relevant professional qualification or membership of professional bodies (if any):

Chartered Accountant ICAEW Membership number 8313878

Address: 56 Flanders Road London W4 1NG

Date: 01/10/2026

Statement of financial activities Year ended 31 December 2025

	Notes	Unrestricted funds £	Restricted funds £	**2025 Total funds £**	2024 Total funds £
Income:					
Donations	2	53,486	101,105	**154,591**	39,565
Bank interest		245	0	**245**	557
Total Income		53,731	101,105	**154,836**	40,122
Expenditure:					
Expenditure on charitable activities	3	56,523	96,105	**152,628**	42,057
Total expenditure		56,523	96,105	**152,628**	42,057
Net income (expenditure)		-2,792	5,000	2,208	-1,935
Net movement in funds		-2,792	5,000	2,208	-1,935
Reconciliation of funds:					
Funds brought forward at 1 January 2024		17,836	6	**17,842**	19,777
Funds carried forward at 31 December 2024		15,044	5,006	**20,050**	17,842

All of the above amounts resulted from the charity's continuing activities during the abover two financial periods.

The notes on pages 19 to 22 form part of these accounts

Balance sheet 31 December 2025

	Notes	2025 £	2024 £
Current assets:			
Debtors	5	**53,786**	30,842
Cash at bank in hand		**22,865**	18,955
		76,651	49,797
Liabilities:			
Creditors: amounts failing due within one year	6	-56,600	-31,955
Total net assets		**20,051**	17,842
The funds of the charity:			
Restricted funds	7	6	6
Unrestricted funds			
General funds	8	20,045	17,836
Total funds		**20,051**	17,842

The notes on pages 19 to 22 form part of these accounts

Statement of cash flows 31 December 2025

	Notes	**2025** £	2024 £
Cash flows from operating activities:			
Net cash provided by operating activities	A	3,665	-40,085
Cash flows from investing activities:			
Bank interested received		245	557
Change in cash and cash equivalents in the year		3,910	-39,528
Cash and cash equivalent at 1 January 2025		**18,955**	58,483
Cash and cash equivalent at 31 December 2025	B	**22,865**	18,955

Notes to the cash flow statement for the year to 31 December 2024

A Reconciliation of net movement in funds to net cash flow from operating activities

	2025 £	2024 £
Net movement in funds (as per statement of financial activities)	**2,208**	-1,935
Interest receivable	**-245**	-557
Decrease/(Increase) in debtors	**-22,944**	11,587
(Decrease) in creditors	**24,646**	-49,180
Net cash provided by operating activities	3,665	-40,085

B Analysis of changes in net debt

	At 1 January 2025 £	Change in Year £	**At 31 December 2025 £**
Cash at bank and in hand	18,955	3,910	22,865

Principal accouting policies 31 December 2025

Basis of preparation
The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are laid out below.

Basis of accounting
These accounts have been prepared for the year to 31 December 2025.

The accounts have been prepared under the historical cost convention with items initially recognised at cost or transaction value unless otherwise stated in the relevant accounting policies below or the notes to these accounts.

The accounts have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) ('Charities SORP FRS 102') issued on 16 July 2014, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

The charity constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in sterling and are rounded to the nearest pound.

Critical accounting estimates and areas of judgement
There are no items in the accounts where trustees have been required to make significant judgements and estimates.

Assessment of going concern
The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts. The trustees have made this assessment in respect to a period of one year from the date of approval of these accounts.

The trustees of the charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the charity to continue as a going concern. The trustees are of the opinion that the charity will have sufficient resources to meets its liabilities as they fall due. In making this assessment, trustees have considered the impact of the coronavirus pandemic on the operational and financial performance of the charity.

Funds structure

Unrestricted income funds are those which the Trustees are free to use for any purpose in furtherance of the charity's objects. Unrestricted funds include designated funds, where the donor has made known their non binding wishes or where the trustees at their discretion, have created the designation for a specific purpose. Restricted funds arise from grants and donations received for specific purposes defined by the donor or the terms of an appeal. Restricted funds relating to income received in connection with the Alliance Boots Biobank project are transferred to the Biobank project through grants made to the EORTC.

Principal accouting policies 31 December 2025

Income

All incoming resources are recognised when the following three factors are met:
1. entitlement – control over the right to the economic benefit has passed to the charity;
2. probable – it is more likely than not that the economic benefits associated with the transaction will flow to the charity;

3. measurement - when the monetary value of the incoming resources can be measured reliably.

Income comprises donations and bank interest.

Donations are recognised when the charity has confirmation of both the amount and settlement date.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

Foreign exchange
Items appearing in the accounts have been translated on the following bases:
- Assets and liabilities: at rates prevailing at the balance sheet date.
- Income and expenditure: at average rates for the year.

Differences arising on exchange are charged or credited to the Statement of Financial Activities.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to make a payment to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. Expenditure comprises direct costs and support costs. All expenses, including support costs, are allocated or apportioned to the applicable expenditure headings. The classification between activities is as follows:

- Expenditure on raising funds includes all expenditure associated with raising funds for the charity

- Expenditure on charitable activities includes all costs associated with furthering the charitable purposes of the charity through the provision of its charitable activities. Such costs include charitable grants and donations, direct and support costs and governance costs.

Grants are made to the EORTC and to the EORTC Cancer Research and for fellowships. A liability for such grants is recognised when approval has been given by the Trustees.

Expenditure (continued)
Other costs includes all expenditure that cannot be analysed into the above two headings.

Contractual arrangements are recognised as goods and services are supplied and are accounted for on an accruals basis.

Irrecoverable VAT is charged against the category of resources expended, for which it was incurred.

Debtors
Debtors are recognised at their settlement amount, less any provision for non-recoverability. Prepayments are valued at the amount prepaid.

Cash at bank and in hand

Cash at bank and in hand represents such accounts and instruments that are available on demand or have a maturity of less than three months from the date of acquisition. Deposits for more than three months but less than one year have been disclosed as short term deposits. Cash placed on deposit for more than one year is disclosed as a fixed asset investment.

Creditors and provisions

Creditors and provisions are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Creditors and provisions are recognised at the amount the charity anticipates it will pay to settle the debt.

Notes to the accounts 31 December 2025

1 Related party transactions

The Friends of EORTC provides financial support to the EORTC Cancer Research Fund and EORTC. The Trustees of the Charity had the following connections with these organisation throughout 2022 and 2025.

	EORTC Cancer Research Fund	EORTC
Diego du Monceau de Bergendal	Chairman of the Council	Board member
Duncan Jodrell	Member of the Council	-
Caroline Artis	Member of the Council	Board member

Grants to EORTC are shown in note 3 below.

None of the trustees received payment for their services to the Charity or reimbursement of expenses by the Charity.

2 Donations

	Unrestricted funds £	Restricted £	2025 £
Donations from individuals and foundations	53,486	100,000	**153,486**
Corporate donations	0	1,105	**1,105**
2025 total funds	53,486	101,105	**154,591**

	Unrestricted funds £	Restricted funds £	2024 £
Donations from individuals and foundations	39,529	0	**39,529**
Corporate donations	0	36	**36**
2025 total funds	39,529	36	**39,565**

3 Charitable expenditure

	Unrestricted funds £	Restricted funds £	2025 £
Direct costs			
Grants awarded		96,105	**96,105**
Liaison office and finance costs	53,442		**53,442**
Bad debt expense			**0**
Support costs			
Governance costs			
Audit and accounting fees	1,200		**1,200**
Rental	600		**600**
Bank and subscription charges	1,281		**1,281**
2025 total funds	56,523	96,105	**152,628**

Notes to the accounts 31 December 2025

3 Charitable expenditure (continued)

	Unrestricted funds £	Restricted funds £	**2024 £**
Direct costs			
Grants awarded		36	**36**
Liaison office and finance costs	39,479		**39,479**
Bad debt expense			**0**
Support costs			
Governance costs			
Audit and accounting fees	1,200		**1,200**
Bank and subscription charges	1,342		**1,342**
2024 total funds	42,021	36	**42,057**

There are no key management personnnel employed by the charity.

4 Comparative Statement of Financial Activities

	Notes	Unrestricted Unrestricted funds £	Restricted funds £	**2024 £**
Income:				
Donations	2	39,529	36	39,565
Bank interest		557		557
Total income		40,086	36	40,122
Expenditure:				
Expenditure on charitable activities	3	42,021	36	42,057
Total expenditure		42,021	36	42,057
Net income (expenditure)		-1,935	0	-1,935
Net movement in funds		-1,935	0	-1,935
Reconciliation of funds:				
Funds brought forward at 1 January 2024		19,771	6	19,777
Funds carried forward at 31 December 2024		17,836	6	17,842

5 Debtors

	2025 £	2024 £
Prepayments and other debtors	53,786	30,842
Gift Aid	0	0
	53,786	30,842

Notes to the accounts 31 December 2025

6 Current liabilities

	2025	2024
	£	£
Amounts failing due within one year:		
Accruals	2,343	31,955
Debt EORTC	816	0
Trade creditors	53,441	0
	56,600	31,955

7 Restricted funds

The income finds of the charity include restricted funds comprising the following unexpended balances.

	At 1 January 2025	Incoming resources	Resources expended	**At 31 December 2025**
	£	£	£	**£**
AmericsourceBergen	-	0	0	**0**
E2-RadiatE	-	1,105	-1,105	**0**
		1,105	-1,105	0

	At 1 January 2024	Incoming resources	Resources expended	**At 31 December 2024**
	£	£	£	**£**
AmericsourceBergen	-	36	-36	**0**
E2-RadiatE	-	0	0	**0**
		36	-36	**0**

AmericsourceBergen

Donations received to this fund are be applied for funding SPECTA (Biobank 1553)

E2-RadiatE

Donations received to this fund are be applied for funding E2-Radiate (1811)

Notes to the accounts 31 December 2025

8 Unrestricted funds

	At 1 January 2024	Incoming resources	Resources expended	**At 31 December 2024**
	£	£	£	**£**
General funds	17,836	53,731	-56,523	15,044
Total unrestricted funds	17,836	53,731	-56,523	15,044

	At 1 January 2024	Incoming resources	Resources expended	**At 31 December 2024**
	£	£	£	**£**
General funds	19,771	40,086	-42,021	17,836
Total unrestricted funds	19,771	40,086	-42,021	17,836